✦ LIBER ✦

Chronic lymphocytic leukemia supervening in non-Hodgkin's lymphoma (diffuse, mixed-cell type)

✍ Scribed by Yasuda, Norimasa; Ohmori, Sei-Ichi; Usui, Tadao

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 476 KB
Volume: 55
Category: Article
ISSN: 0361-8609
DOI: 10.1002/(sici)1096-8652(199705)55:1<52::aid-ajh13>3.0.co;2-8

No coin nor oath required. For personal study only.

✦ Synopsis

administered to reduce the drug's cost, remains to be determined. This case demonstrates that a short-term regimen of erythropoietin and iron supplementation may allow high-dose chemotherapy to be offered to those individuals unwilling to accept blood products.

📜 SIMILAR VOLUMES

Occult lymphoma cells prevalent in autol

Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma

✍ Junkichi Yokoyama; Yoshiaki Fujimiya; Toshikazu Yamaguchi; Kiyoto Shiga; Yoshio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB 👁 1 views

Increased survival associated with radio

Increased survival associated with radiolabeled lym-1 therapy for non-hodgkin's lymphoma and chronic lymphocytic leukemia

✍ Gerald L. DeNardo; Kathleen R. Lamborn; Desirée S. Goldstein; Linda A. Kroger; S 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

on baseline Karnofsky performance status (KPS) and serum lactic dehydrogenase California. (LDH) predicted response and survival and was used to define risk groups. Propor-2 Brain Tumor Research Center, Department of tional-hazards, Kaplan-Meier, and Landmark models were used to evaluate pa-Neurolog

Polymorphisms in xenobiotic-metabolizing

Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients

✍ Olga A. Gra; Andrey S. Glotov; Eugene A. Nikitin; Oleg S. Glotov; Viktoria E. Ku 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Tumor lysis syndrome occurring after the

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

✍ Yang, Honghao; Rosove, Michael H.; Figlin, Robert A. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 2 views

Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re

LETTER TO THE EDITOR. LOW VERSUS HIGH CE

LETTER TO THE EDITOR. LOW VERSUS HIGH CELL TURNOVER IN DIFFUSELY GROWING NON-HODGKIN'S LYMPHOMAS

✍ YAVORKOVSKY, LEONID L. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

high PI of a tumour is in itself a result of a later genetic event following initial transformation-a phenomenon of tumour progression at presentation. The role of proliferation parameters in predicting tumour behaviour has been contr~versial.~,~ However, assessment of turnover index could prove to

Severe myelotoxicity of oral etoposide i

Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia

✍ Sharon Shaklai; Osnat Bairey; Dorit Blickstein; Miron Prokocimer; Herzlia Hadar; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB 👁 2 views

## BACKGROUND. Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. Due to the small number of patients reported, information regarding side effects is limited, and therefore warrants further evaluation. ## METHODS. Twenty eligible